How big is IDEXX Laboratories, Inc.?

As of Jun 18, IDEXX Laboratories, Inc. has a market capitalization of $53.28 billion, with net sales of $3.93 billion and net profit of $894.97 million over the latest four quarters.

As of Jun 18, IDEXX Laboratories, Inc. has a market capitalization of 53,281.30 million, categorizing it as a Large Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 3,931.84 million, while the sum of Net Profit for the same period is 894.97 million.<BR><BR>As of Dec 24, the reporting period for the balance sheet shows Shareholder's Funds at 1,595.31 million and Total Assets at 3,293.44 million.

What does IDEXX Laboratories, Inc. do?

IDEXX Laboratories, Inc. develops and distributes products for veterinary, livestock, and water testing markets, with recent net sales of $998 million and a market cap of $53.28 billion. Key financial metrics include a P/E ratio of 60.00 and a return on equity of 61.71%.

Overview:<BR>IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services for the companion animal veterinary, livestock and poultry, dairy, and water testing markets, operating within the Pharmaceuticals & Biotechnology industry and classified as a large-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 998 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 243 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 53,281.30 Million (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 60.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.55 <BR>Return on Equity: 61.71% <BR>Price to Book: 36.80<BR><BR>Contact Details:<BR>Address: 1 Idexx Dr, WESTBROOK ME: 04092-2041 <BR>Tel: 1 207 5560300 <BR>Fax: 1 207 5564346 <BR>Website: https://www.idexx.com/

Should I buy, sell or hold IDEXX Laboratories, Inc.?

Who are in the management team of IDEXX Laboratories, Inc.?

As of March 2022, the management team of IDEXX Laboratories, Inc. includes Lawrence Kingsley (Independent Chairman), Jonathan Mazelsky (President & CEO), and several independent directors: Jonathan Ayers, Bruce Claflin, Asha Collins, Stuart Essig, and Rebecca Henderson. They oversee the company's strategic direction and operations.

As of March 2022, the management team of IDEXX Laboratories, Inc. includes the following individuals:<BR><BR>- Mr. Lawrence Kingsley, Independent Chairman of the Board<BR>- Mr. Jonathan Mazelsky, President, Chief Executive Officer, Director<BR>- Mr. Jonathan Ayers, Director<BR>- Mr. Bruce Claflin, Independent Director<BR>- Dr. Asha Collins, Independent Director<BR>- Dr. Stuart Essig, Independent Director<BR>- Dr. Rebecca Henderson, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Is IDEXX Laboratories, Inc. technically bullish or bearish?

As of October 3, 2025, IDEXX Laboratories, Inc. shows a mildly bullish trend supported by monthly MACD and KST indicators, despite short-term bearish signals from weekly MACD and RSI, while outperforming the S&P 500 year-to-date and over the past year, but lagging in longer periods.

As of 3 October 2025, the technical trend for IDEXX Laboratories, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the monthly MACD and KST indicators, which are both bullish, while the daily moving averages also indicate a mildly bullish trend. However, the weekly MACD and RSI are bearish, suggesting some short-term weakness. The Bollinger Bands are mildly bullish on both weekly and monthly time frames, supporting the overall mildly bullish outlook. <BR><BR>In terms of multi-period returns, IDEXX has outperformed the S&P 500 year-to-date and over the past year, with returns of 51.84% and 31.43% respectively, compared to the S&P 500's 14.18% and 17.82%. However, over longer periods, such as 3 years and 5 years, IDEXX has lagged behind the S&P 500.

Is IDEXX Laboratories, Inc. overvalued or undervalued?

As of October 17, 2025, IDEXX Laboratories, Inc. is fairly valued with a P/E ratio of 60, an EV to EBITDA of 42.53, and a PEG ratio of 11.32, indicating a premium compared to peers like Abbott Laboratories and Thermo Fisher Scientific, while outperforming the S&P 500 with a year-to-date return of 53.69%.

As of 17 October 2025, the valuation grade for IDEXX Laboratories, Inc. moved from expensive to fair. The company appears fairly valued based on its current metrics. Key ratios include a P/E ratio of 60, an EV to EBITDA of 42.53, and a PEG ratio of 11.32, which suggest that while the company is not undervalued, it is also not excessively priced compared to its peers.<BR><BR>In comparison to its industry peers, IDEXX Laboratories has a higher P/E ratio than Abbott Laboratories at 18.36 and Thermo Fisher Scientific at 30.06, indicating a premium valuation. However, it is more competitively positioned than Intuitive Surgical, which has a P/E of 63.32. Notably, IDEXX has demonstrated strong returns, with a year-to-date return of 53.69% compared to the S&P 500's 13.30%, reinforcing its relative strength in the market.